Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Trade Desk Inc (TTD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Trade Desk Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.8 (market cap $4.49B), while Trade Desk Inc trades at $19.09 (market cap $9.02B). The key difference: Trade Desk Inc is far larger — about 2× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | TTD | |
|---|---|---|
Market Cap | $4.49B | $9.02B |
Sector | Health | Technology |
52-Week High | $28.06 | $89.76 |
52-Week Low | $20.06 | $17.33 |
Enterprise Value | $3.69B | $8.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
The Trade Desk (TTD) trades at $19.18, up 0.42% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though Q1 2026 earnings missed expectations. Revenue growth has been consistent, reaching $2.9B in 2025, while analyst sentiment remains divided with a $25.46 consensus target representing 33% upside potential.
TTD presents a compelling value opportunity with reasonable valuations (P/E 21.94, P/S 3.17) and strong cash flow generation, but faces near-term headwinds from recent earnings miss and competitive pressures in digital advertising. The stock's 86% decline from 2024 highs creates potential for recovery if execution improves, though investor caution is warranted given mixed analyst ratings and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
